Navigation Links
Rockland Immunochemicals, Inc. CSO Opines “Benefits of Polyclonal Antibodies” in peer-reviewed article
Date:8/9/2018

Rockland Immunochemicals, Inc. announced today that Dr. Carl Ascoli, Chief Science Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed article using their combined experience of more than 50 years. The review article was published online on August 9, 2018 and will be printed in the September 2018 issue by the journal BioTechniques. The review article, entitled "The Overlooked Benefits of Polyclonal Antibodies,” discusses the pros and cons of polyclonal, conventional monoclonal, and recombinant monoclonal antibodies, while presenting procedures for experimental design, the inclusion of relevant controls, and validation strategies for polyclonal antibodies.

Antibodies are critical reagents most often used by life science and translational medicine researchers and are transformative tools used to diagnose and treat disease. Many 21st century medical breakthroughs were successful in part to antibody technology. Yet antibodies, especially polyclonal antibodies, are caught in a firestorm of controversary concerning data reproducibility. Ascoli stated “by emphasizing the appropriate role polyclonal antibodies may play in conducting life science research, our efforts here should improve upon the use of antibodies, the collection of reproducible data, and the expansion of antibody-based technologies.”

Thoughtful antibody design and development allows for polyclonal antibodies to be used in many different applications, techniques, and instrumentation. Ascoli explained that “while some have called for polyclonal antibodies to be phased out of research entirely, we believe in using ‘the right tool for the job’ which includes using all forms of antibodies, polyclonal, conventional monclonal, and recombinant monoclonal, in the appropriate context and according to the manufacturer’s recommendations.” When using polyclonal antibodies, it is particularly important to use appropriate positive and negative controls and to assure immunoassay-specific antibody validation on a lot-to-lot basis. This review article presents the value of polyclonal antibodies for research, discusses strategies to minimize their disadvantages, and suggests when other forms of antibodies are more appropriate.

To read the full peer-reviewed article, please visit: https://www.future-science.com/doi/10.2144/btn-2018-0065

# # #

TO THE EDITOR:
Rockland Immunochemicals, Inc., (Rockland) provides the highest quality antibodies and antibody-based life science tools and services to the academic, biopharma, and diagnostic industries for use in basic research, assay development, preclinical and clinical studies, and bioprocessing. With facilities in Pennsylvania for over 55 years, Rockland manufactures products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA, flow cytometry, and 2D imaging.
Additional information about Rockland’s life science tools and services can be found on Rockland’s website at http://www.rockland-inc.com.

Christina Rowley
Marketing Communications Manager
Rockland Immunochemicals, Inc.
Phone: 484.791.3823
Email: christina.rowley(at)rockland-inc.com

Read the full story at https://www.prweb.com/releases/rockland_immunochemicals_inc_cso_opines_benefits_of_polyclonal_antibodies_in_peer_reviewed_article/prweb15670368.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Rockland Immunochemicals, Inc. Partners with Alex’s Lemonade Stand Foundation to Support Early Career Childhood Cancer Researchers
2. The Binding Site & Rockland Immunochemicals Enter Into Distribution Agreement
3. Rockland Immunochemicals, Inc. Introduces Melanoma Cell Lines in Collaboration with The Wistar Institute
4. uBiome Publishes Peer-Reviewed Scientific Paper in PLOS ONE on First Version of Technology for Gut Health Screening Test
5. Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinsons LID
6. CardioCell Board Members and Clinical Trial Leads Collaborate on Peer-Reviewed Paper Published in the Journal of Cardiovascular Medicine
7. Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics Novel Small-Molecule Approach to Cancer Treatment
8. Mechanism of Action of ABIVAXs First-in-class Anti-HIV Drug Published Today in Peer-reviewed Journal Retrovirology
9. Newly Released Peer-Reviewed Publication Further Validates RepliCels Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
10. MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal
11. Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society of Gene & Cell ... team, including a new addition to the presidential line of succession, at the ... the Society's leadership team for a three-year term (2019-2021). , All five incoming members ...
(Date:4/8/2019)... ... 08, 2019 , ... US Capital Global Securities , an affiliate of ... in the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline ... hypoactive sexual dysfunction disorder and is ready to begin phase 2b trials. In phase ...
(Date:4/4/2019)... ... 2019 , ... Biomeme, Inc. , a leading manufacturer ... solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called Franklin ™. ... an English chemist and X-ray crystallographer who made significant contributions to the understanding ...
Breaking Biology Technology:
(Date:4/4/2019)... ... 2019 , ... Orbsen Therapeutics, a biotechnology company focused on ... move its base of operations from the National University of Ireland (NUI) Galway ... in Galway, Ireland. , “With four clinical trials in full swing and the ...
(Date:4/4/2019)... ... 03, 2019 , ... R3 Stem Cell is now offering ... of Excellence. R3 wants patients to feel secure when they make a significant ... Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a safe ...
(Date:3/29/2019)... (PRWEB) , ... March 28, 2019 , ... In the ... not directly prescribe a path for this task. Despite this uncertainty, several manufacturers have ... of today. In the first part of this webinar, learn how analytical similarity is ...
Breaking Biology News(10 mins):